Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis
Therapeutic Advances in Respiratory Disease · 2025
DOI: 10.1177/17534666251336896 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Ophir Freund und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence for Interstitial Lung Diseases, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic, Immunosuppressive Agents, Myositis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Interstitial lung disease (ILD) is the main clinical feature of antisynthetase syndrome (ASS). In the absence of randomized controlled trials to guide therapy, treatment strategies are often extrapolated from other diseases, mainly systemic sclerosis (SSc).
Objectives
Our aim was to evaluate the dynamics of ILD severity following immunosuppressive treatment (IST) in ASS compared to SSc.
Design
A multicenter retrospective observational study.
Methods
ASS ( n = 22) and SSc ( n = 32) subjects with ILD were included in the registries of three medical centers. All patients received ISTs. We analyzed changes in forced vital capacity (FVC) and diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) after treatment initiation using linear mixed-effects models. Changes in high-resolution chest CT scans were analyzed by a radiologist blinded to clinical data.
Results
The median (interquartile range) age was 66 (59–71), 72% were females, and 81% of IST included mycophenolate mofetil (MMF). Baseline demographics, comorbidities, and pulmonary functions were similar between the groups. Among the ASS group, the mixed-effects models showed significant improvements in FVC% ( F = 11.3, p < 0.01) and DLCOc% ( F = 7.1, p = 0.015) after treatment initiation over time, while in the SSc group, there were no significant changes in FVC% ( F = 0.4, p = 0.551) and DLCOc% ( F = 0.8, p = 0.384). Changes in FVC% and DLCOc% were higher in the ASS group compared with SSc ( p = 0.017 and p < 0.01, respectively), which persisted after adjustment to steroid use and in a sub-analysis of patients with serial pre- and post-IST pulmonary functions. Both groups had improved total CT scores after IST, without changes in other radiologic scores.
Conclusion
Immunosuppressive treatment, mostly with MMF, was associated with significant improvement of FVC% and DLCOc% in ASS, compared to their stabilization only in SSc. This should encourage future randomized controlled studies of MMF in ASS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence for Interstitial Lung Diseases, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Institute of Pulmonary Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Rheumatology department, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Radiology, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Pulmonary Medicine, Barzilai University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Be'er Sheva, Israel.
ORCID-Profile: Ophir Freund, Avraham Unterman
Zitieren
APA
Freund, O., Eviatar, T., Meidan, R., Shalmon, T., Stav, D., Hershko, T., Perluk, T. M., Wand, O., Schneer, S., Adir, Y., Shitrit, D., Elkayam, O., Bar-Shai, A., & Unterman, A. (2025). Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251336896
Vancouver
Freund O, Eviatar T, Meidan R, Shalmon T, Stav D, Hershko T, et al. Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251336896
BibTeX
@article{Freund2025,
author = {Freund, Ophir and Eviatar, Tali and Meidan, Roni and Shalmon, Tamar and Stav, Dana and Hershko, Tzlil and Perluk, Tal Moshe and Wand, Ori and Schneer, Sonia and Adir, Yochai and Shitrit, David and Elkayam, Ori and Bar-Shai, Amir and Unterman, Avraham},
title = {Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
doi = {10.1177/17534666251336896}
}
EUVIMED